Ocular Rheumatologist | @WUSTL_Rheum @WUDeptMedicine | T cell biology and scRNAseq/TCRseq | full of dry and nerdy humor
St. Louis, MO
Joined May 2021
- Tweets97
- Following174
- Followers298
- Likes178
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
An enteric start to HLA-B27-associated autoimmune disease? insight.jci.org/articles/vie…
Work from @drmapaley, @XinboYang777 et al. suggests early antigen exposure in gut leads to pathogenic CD8+ T cell development in axial spondyloarthritis & acute anterior uveitis.
@WUSTLmed
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
Pharmacy benefit managers act as middlemen overseeing prescriptions for millions of Americans to reduce drug costs. A New York Times investigation found they charge steep prices for patients, employers and the government. Our reporter explains how. nyti.ms/3RESDih
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
🎙Dive into the latest episode of Spondycast, where host Jill Miller & award-winning ocular rheumatologist @drmapaley enlighten us on his groundbreaking research! Check it out here: spondylitis.org/podcasts #inflammation #uveitis #gut #microbiome
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
"total number of TCRs in a human, supports Mason’s notion that we should #abandon the ‘one-clonotype–one-specificity’ paradigm suggested by clonal selection theory in favour of a ‘one-clonotype–millions-of‑specificities’reality" nature.com/articles/nri3279
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
Thank you, @spondylitis, for awarding Dr. Michael Paley with this years ECI Award! We are so proud of the work he does to help those suffering from #SpA related diseases! ❤️
@drmapaley #ACR23
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
Another great year at #ACRKnowledgeBowl! Congratulations to the finalists and fingers crossed our #WashUComplementCommanders take home the #ACR23 Spirit Award! @ACRheum @WUSTL_Rheum
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
Another epic SPARTAN #ankylosingspondylitis meeting with @drmapaley and @tejpalgill ..check out that @CureArthritis gear!) 🔥
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
Authored by Andrew G. Soerens et al, we show that #Tcells are capable of proliferating in response to iterative stimulation for over 10yrs! And produce enough progeny to occupy a volume 30,000x the Earth's volume! @Nature nature.com/articles/s41586-0…
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
Great talk by @alhkim today at the @WUSTL_Rheum Translational Research Conference on immunosupression and SARS-CoV-2 vaccination! Great work again by all of the collaborators (too many to tag)! @IbdWustl @WashUID @WUSTLneurosci @wusm_pathology @UCSFRheum #Research #COVID19
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
Thanks a lot, Michael! This work is a great example of collaboration makes the progress of Science! I am very grateful to work with you all!!
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
See the published paper here: nature.com/articles/s41586-0… @WUDeptMedicine @WUSTL_Rheum (2/9)
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
Get to know #WUPhysicianScientist Dr. Tarin Bigley! @BigleyLab @WUSTLPeds @WUSTL_Rheum
Meet our new faculty member Tarin Bigley, MD, PhD (@BigleyLab)!
Bigley was born in Arizona but grew up in South Milwaukee, Wisconsin. Growing up, when he wasn’t in school...
Hear the rest of his story!
news.peds.wustl.edu/faculty-…
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
Thrilled to present our analysis of the relationship between the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine in immunosuppressed patients with chronic inflammatory disease in the @COVaRiPAD cohort, now out in @ACR_Journals: onlinelibrary.wiley.com/doi/…
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
Happy STL Day (3/14)!
We are so proud to be a part of this incredible community! Thank you for choosing us to be your rheumatologists!
@WUDeptMedicine @WashUDPS
#chooserheum #rheumrules
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
We have a long way to go but we won’t stop advocating for our patients. Just like our very own @alhkim who was interviewed for this article! Thank you, @edyong209 for writing this important piece!
theatlantic.com/health/archi…
@WUDeptMedicine #immunocompromised #COVIDvaccine
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
This Post is from an account that no longer exists. Learn more
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
We had a great ROSCE today with our friends in Rheum at @CUMedicalSchool! Thank you so much to @MetroTheater, @IreneBlancoMD and our faculty for assisting in this great teaching experience for our #RheumFellows! @LisaZickuhr @JKolfenbach @md_reema @alhkim #MedEd
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
Congratulations to our very own Dr. Iris Lee on receiving the 2022 Dean's Scholar Award! 🎉
@WUDeptMedicine @WashUDPS
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
ORAL Surveillance, open label RCT of tofa vs. TNF, published @NEJM, aka Sword of Damocles has finally fallen
In short, TOFA associated with ⬆️ risk of major adverse cardiac events (MACE) (HR 1.33, CI 0.91-1.94) & ⬆️ risk of cancer (HR 1.48, CI 1.04-2.09)
Much to unpack, a 🧵
Michael Paley, M.D., Ph.D. (moving to @Bluesky) retweeted
“Rheumatology education needs a splash of color!” Check out the editorial in this month’s @jrheum, where Wash U’s @LisaZickuhr and @ClevelandClinic Brian Mandell call educators to represent patients of all skin tones in teaching materials. doi.org/10.3899/jrheum.21123…